Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A pharmaceutical composition for preventing or treating acute and chronic liver disease

An acute and chronic combination technology, applied in drug combination, drug delivery, organic active ingredients, etc., to prevent liver cell necrosis, improve transmembrane process, and inhibit collagen production

Inactive Publication Date: 2006-12-20
CHENGDU ZIHAO PHARMA
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Drugs that promote liver tissue regeneration, fully restore liver function, and prevent hepatic steatosis (fatty liver) and liver fibrosis are the key development directions in the field of liver disease treatment. There are no new drug reports in this area so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] The essential phospholipid 1.2g, 15g of Salvia miltiorrhiza or 15g of Schisandra or 15g of licorice in the treatment of liver injury, directly uses the water extract of the medicinal material.

[0036] method:

[0037] Randomly divide the phospholipid danshen group, phospholipid schisandra group, phospholipid licorice group and essential phospholipid group, danshen group, schisandra group, licorice group and positive drug (diammonium glycyrrhizinate capsule), negative group (blank control group), and model components into ten groups , Use wistar rats, weighing 180-220g, male and female, 10 rats in each group for the test. Negative control group: 1% CMC gavage, dosage 1ml / 100g; model group: 1% CMC gavage, dosage 1ml / 100g; test drug group administration dosage of full prescription group 140mg / kg, essential phospholipid group 160mg / kg, Danshen Group 120mg / kg, positive group 40mg / kg, gavage once a day, continuous administration for 7 days, 1h after gavage on the 8th day, except...

Embodiment 2

[0046] The use of essential phospholipids 1.2g, Bupleurum 5-30g, and licorice 5-30g in the treatment of chronic hepatitis B cirrhosis.

[0047] method:

[0048] Same model and administration method as in Example 1, but with two dosage groups

[0049] Whole prescription group 1: essential phospholipids 1.2g Bupleurum 15g licorice 15g;

[0050] All prescription group 2: Essential phospholipids 1.2g, Bupleurum 30g, and licorice 30g.

[0051] The medicinal materials are directly used to prepare the water extract, and the necessary phospholipids are added.

[0052] The main observation indexes were 48 hours after intraperitoneal injection of D-galactosamine, the animals were sacrificed, and the liver of the rats was taken to determine the liver coefficient and pathological changes.

[0053] The criteria for judging liver tissue pathological damage are shown in the following table:

[0054] Pathological changes grade

Pathological feature description

Edema and Degener...

Embodiment 3

[0062] Essential phospholipids 1.2g Alisma 5-30g Panax notoginseng 5-30g Turmeric 5-30g Salvia 5-30g

[0063] In the treatment of dietary fatty liver, and has the effect of significantly reducing the triglycerides and cholesterol of hyperlipidemia. method:

[0064] Randomly divide the whole prescription group, essential phospholipid group, traditional Chinese medicine group (except essential phospholipids), positive group (Xuezhikang Capsule), blank control group, and model components into 7 groups. The full prescription components are:

[0065] Whole prescription group 1: Essential phospholipids 1.2g Alisma 10g Panax notoginseng 5g Turmeric 5g Salvia 5g

[0066] All prescription group 1: Essential phospholipids 1.2g Alisma 20g Panax notoginseng 10g Turmeric 10g Salvia 10g. The medicine is directly prepared from medicinal materials into an aqueous extract, and essential phospholipids are added.

[0067] The experiment used healthy male SD rats, 10 in each group, weighing about 120...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating or preventing acute and chronic hepatic disease, which is prepared from Chinese medicinal herbs including Bupleurum root, licorice root, root of red rooted saliva, notoginseng, schisandra fruit, curcuma longa, picrorhiza rhizome, cow-bezoar, Chinese angelica root, herba patriniae, astragalus root and alisol. The invention also provides the method for preparation and use of the pharmaceutical composition.

Description

Technical field [0001] The invention relates to a pharmaceutical composition for the prevention or treatment of acute and chronic liver diseases, in particular to a pharmaceutical composition for the treatment of acute and chronic liver diseases, which mainly takes natural medicine ingredients as effective ingredients. Background technique [0002] According to investigations, there are 12 million patients suffering from chronic hepatitis in my country, and about 300,000 deaths from liver diseases each year, of which 50% are primary hepatocellular carcinoma, and the vast majority are related to hepatitis B and C virus infections. Viral hepatitis is an infectious disease that seriously endangers the health of the people of our country. Among the legally reported infectious diseases, the incidence and mortality of viral hepatitis occupy the first place, with an average annual incidence of about 100 / 100,000, which means that the country’s annual incidence of acute There are about 1....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/9066A61K9/08A61K9/10A61K9/14A61K9/19A61K9/20A61K9/48A61P1/16A61K35/413A61K31/714A61K31/375A61K31/661
Inventor 谢雷谭万芳
Owner CHENGDU ZIHAO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com